RxDoctor Payments Data

Anne Wishna, MD

Ophthalmology · Kansas City, KSNPI 1215084439

Payments from drug & device makers

$1,485in general payments, 2019–2025

Across 46 payments — averaging $32.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$390
  • Glaukos Corporation$349
  • AbbVie$141
  • Carl Zeiss Meditec USA, Inc.$86
  • Aerie Pharmaceuticals, Inc.$85
  • Sight Sciences, Inc.$53
  • plus $381 from 11 others

What the payments were for

  • Food & beverage$1,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,485 in reported general payments places this provider in the 50th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$152,903
Medicare patients
638
Services billed
1,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine124$121,997
XiidraLifitegrast87$73,152
Cyclosporine66$31,384
Restasis MultidoseCyclosporine20$19,250
IlevroNepafenac30$10,820
CombiganBrimonidine Tartrate/Timolol14$5,984
Prednisolone Acetate122$5,732
Difluprednate45$4,941
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$3,507
Travatan ZTravoprost13$3,034
Ketorolac Tromethamine96$2,653
Fluorometholone24$2,138
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,920
Latanoprost130$1,672
Bromfenac Sodium14$1,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Combigan$141$147,231158 claims
Bausch & Lomb Americas Inc.Xiidra$42$73,15287 claims
NovartisIlevro, Travatan Z$49$13,85443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →